BPHA

CAT: 0804-HY-114785-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-114785-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BPHA is a potent and orally active MMP-2, MMP-9 and MMP-14 inhibitor with IC50s of 12 nM, 16 nM and 17 nM, respectively. BPHA does not inhibit MMP-1, -3, and -7 (the IC50s are 974, >1000, and 795 nM, respectively) . BPHA has antiangiogenic and antitumor effects[1].
CAS Number
[193807-60-2]
Product Name Alternative
Flufenamic acid butyl ester; Butyl flufenamate, MC 903; Calcipotriene
UNSPSC
12352005
Hazard Statement
H228-H315-H319
Target
MMP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bpha.html
Purity
99.88
Solubility
DMSO : 350 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=C(C2=CC=CC=C2)C=C1)(N[C@H](CC3=CC=CC=C3)C(NO)=O)=O
Molecular Formula
C21H20N2O4S
Molecular Weight
396.46
Precautions
P210-P240-P241-P264-P280-P302+P352-P305+P351+P338-P362+P364-P370+P378
References & Citations
[1]R Maekawa, et al. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar 15;59 (6) :1231-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-1; MMP-14; MMP-2; MMP-3; MMP-7; MMP-9